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955Immortal Time Bias and
the Use of IVC FiltersWe commend the RIETE (Computerized Registry
of Patients with Venous Thromboembolism) group
for attempting to analyze the beneﬁts of use of an
inferior vena cava (IVC) ﬁlter after acute pulmonary
embolism (PE) using their large prospectively col-
lected registry (1). Their propensity-matched analysis
showed a lower risk-adjusted PE-related mortality
rate in patients who received an IVC ﬁlter compared
those who did not. However, we wish to point out
a signiﬁcant source of bias in this observational
study that cannot be adjusted for with the use of
propensity matching.
The bias we refer to is termed “immortal time bias”
(2). This bias is frequently encountered when
analyzing the effectiveness of an intervention, such
as use of an IVC ﬁlter, when using observational data.
The placement of a ﬁlter also depends on meeting
some clinical criteria, having a physician available to
place the ﬁlter, and the patient’s clinical condition.
In more critically ill patients, insertion of a ﬁlter
may not be possible and death may occur before
placement of the ﬁlter. In analyzing the data, if
simply comparing the outcomes of patients with an
IVC ﬁlter versus those without, the results are biased.
All patients who received a ﬁlter were alive at the
time of the procedure (hence, they were “immortal”
up to the time the ﬁlter was placed), whereas the
patients who did not receive a ﬁlter included those
who may have died before a ﬁlter could be placed.
This distinction between the 2 groups is important;
upwards of 30% of PE-related mortality occurs within
the ﬁrst 24 h of hospitalization (3). In the study by
Muriel et al. (1), in the patients who received an IVC
ﬁlter, the authors started the clock on the primary
outcome of 30-day mortality on the day the ﬁlter was
placed; however, in the patients who did not receive
a ﬁlter, it was considered to be when anticoagulation
was started. A better way of analyzing these data
would be to use the admission date or the date of
diagnosis of PE as the anchor time and model death
due to PE by using a Cox proportional hazard model,
entering use of an IVC ﬁlter as a time-dependent
covariate. The hazard associated with use of a ﬁlter is
compared with the hazard of not using a ﬁlter in
patients who are alive on the same day. Using this
methodology, all patients who were not treated with
a ﬁlter but who died early after diagnosis of PE
are excluded from calculation of the relative hazard
associated with use of a ﬁlter. Alternatively, patients
could be matched on both propensity score and beingalive on the day of placement of the ﬁlter, thereby
excluding those who died before the intervention
could be completed. We suggest that the authors use
one of these suggested methodologies to determine
if the hazard ratio for PE-related mortality is similar
or signiﬁcantly different between those with and
without a ﬁlter.
The authors raise several interesting points, but
we ultimately agree with the conclusion of Dr. Morris
in the accompanying editorial (4). The onlyway to truly
settle the controversial issue of whether ﬁlters are
beneﬁcial in patients who cannot be anticoagulated
is by conducting a well-designed clinical trial.
However, performing such a trial will be difﬁcult.
Informed consent will have to be obtained quickly,
followed by rapid randomization and expeditious
insertion of the IVC ﬁlter. Until that time, clinicians
must try to make inferences from observational
studies that have unmeasured confounders as well as
immortal time bias. We believe the results of such
analyses should not have any major impact on
venous thromboembolism guidelines or clinical
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Richard H. White, MD
*Division of Pulmonary, Critical Care and Sleep Medicine
University of California, San Diego
9500 Gilman Drive, Mail Code #0643
La Jolla, California 92093-0643
E-mail: tfernandes@ucsd.edu
http://dx.doi.org/10.1016/j.jacc.2014.04.075
REF ER ENCES
1. Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava
ﬁlter in patients with acute symptomatic venous thromboembolism and a
signiﬁcant bleeding risk. J Am Coll Cardiol 2014;63:1675–83.
2. Linda EL, James AH, Abbas K, Samy S. Problem of immortal time bias in
cohort studies: example using statins for preventing progression of diabetes.
BMJ 2010;340:b5087.
3. Casazza F, Becattini C, Bongarzoni A, et al. Clinical features and short term
outcomes of patients with acute pulmonary embolism. The Italian Pulmonary
Embolism Registry (IPER). Thromb Res 2012;130:847–52.
4. Morris TA. Do inferior vena cava ﬁlters prevent death from pulmonary
embolism? J Am Coll Cardiol 2014;63:1684.REPLY: Immortal Time Bias and the
Use of IVC FiltersWe thank Drs. Fernandes and White for their
thoughtful comments about our registry-based retro-
spective cohort study of patients with acute venous
thromboembolism (1). We agree that the start time of
follow-up and treatment status in the design and
analysis of our study (1) might have introduced
